drugset / Trial / NCT03789734
Safety Study of BLS-M22 in Healthy Volunteers
RandomizedSequentialQuadruple-blindTreatment
Summary
BLS-M22 is being developed as an anti-myostatin agent for the treatment of Duchenne Muscular Dystrophy (Muscular Dystrophy). A total of 37 subjects participated in this study to confirm the safety of BLS-M22.
Timeline
- Start
- 2019-06-04
- Primary completion
- 2020-04-23
- Completion
- 2020-11-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BLS-M22 | Unknown | 500 mg | Oral |
| Subject | BLS-M22 | Unknown | 1000 mg | Oral |
| Subject | BLS-M22 | Unknown | 2000 mg | Oral |